Acino Holding AG (XSWX:ACIN) Days Sales Outstanding : 77.14 (As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Acino Holding AG Days Sales Outstanding?

Acino Holding AG's average Accounts Receivable for the six months ended in Dec. 2013 was CHF67.9 Mil. Acino Holding AG's Revenue for the six months ended in Dec. 2013 was CHF321.2 Mil. Hence, Acino Holding AG's Days Sales Outstanding for the six months ended in Dec. 2013 was 38.57.

The historical rank and industry rank for Acino Holding AG's Days Sales Outstanding or its related term are showing as below:

XSWX:ACIN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.35 Med: 56.98 Max: 116.4
Current: 74.67

During the past 11 years, Acino Holding AG's highest Days Sales Outstanding was 116.40. The lowest was 1.35. And the median was 56.98.

XSWX:ACIN's Days Sales Outstanding is not ranked
in the Drug Manufacturers industry.
Industry Median: 71.68 vs XSWX:ACIN: 74.67

Acino Holding AG's Days Sales Outstanding declined from Dec. 2011 (85.89) to Dec. 2013 (77.14).

Acino Holding AG Days Sales Outstanding Historical Data

The historical data trend for Acino Holding AG's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acino Holding AG Days Sales Outstanding Chart

Acino Holding AG Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Days Sales Outstanding

Get a 7-Day Free Trial

42.44

92.34

85.89

56.31

77.14

Acino Holding AG Semi-Annual Data
	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13
Days Sales Outstanding	Get a 7-Day Free Trial						42.44	92.34	85.89	56.31	77.14

Competitive Comparison of Acino Holding AG's Days Sales Outstanding

For the Drug Manufacturers - General subindustry, Acino Holding AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acino Holding AG's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Acino Holding AG's Days Sales Outstanding falls into.

Acino Holding AG Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Acino Holding AG's Days Sales Outstanding for the fiscal year that ended in Dec. 2013 is calculated as

	Days Sales Outstanding (A: Dec. 2013 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2012 )	+	Accounts Receivable (A: Dec. 2013 ))	/	count )	/	Revenue (A: Dec. 2013 )	*	Days in Period
=	( (70.05	+	65.699)	/	2 )	/	321.15	*	365
=	67.8745					/	321.15	*	365
=	77.14

Acino Holding AG's Days Sales Outstanding for the quarter that ended in Dec. 2013 is calculated as:

	Days Sales Outstanding (Q: Dec. 2013 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2012 )	+	Accounts Receivable (A: Dec. 2013 ))	/	count )	/	Revenue (A: Dec. 2013 )	*	Days in Period
=	( (70.05	+	65.699)	/	2 )	/	321.15	*	365 / 2
=	67.8745					/	321.15	*	365 / 2
=	38.57

Acino Holding AG (XSWX:ACIN) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Acino Holding AG Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Acino Holding AG's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Acino Holding AG (XSWX:ACIN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acino Holding AG (XSWX:ACIN) » Definitions » Days Sales Outstanding

Traded in Other Exchanges

N/A

Address

Website

http://www.acino-pharma.com

Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.

Acino Holding AG (XSWX:ACIN) Headlines

No Headlines